GENFIT S.A. (GNFT): Price and Financial Metrics


Today's Latest Price: $4.47 USD

0.02 (0.45%)

Updated Oct 23 4:00pm

Add GNFT to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

GNFT Stock Summary

  • Genfit SA's stock had its IPO on March 27, 2019, making it an older stock than only 2.53% of US equities in our set.
  • Revenue growth over the past 12 months for Genfit SA comes in at 422.82%, a number that bests 98.35% of the US stocks we're tracking.
  • The volatility of Genfit SA's share price is greater than that of 96.07% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to GNFT, based on their financial statements, market capitalization, and price volatility, are VNE, IPHA, IMOS, INFI, and HIMX.
  • Visit GNFT's SEC page to see the company's official filings. To visit the company's web site, go to

GNFT Stock Price Chart Interactive Chart >

Price chart for GNFT

GNFT Price/Volume Stats

Current price $4.47 52-week high $22.48
Prev. close $4.45 52-week low $3.65
Day low $4.25 Volume 20,400
Day high $4.47 Avg. volume 78,382
50-day MA $4.70 Dividend yield N/A
200-day MA $10.36 Market Cap 169.11M

GENFIT S.A. (GNFT) Company Bio

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné and Bart Staels on September 1999 and is headquartered in Loos, France.

GNFT Latest News Stream

Event/Time News Detail
Loading, please wait...

GNFT Latest Social Stream

Loading social stream, please wait...

View Full GNFT Social Stream

Latest GNFT News From Around the Web

Below are the latest news stories about Genfit SA that investors may wish to consider to help them evaluate GNFT as an investment opportunity.

GENFIT SA (GNFT) CEO Pascal Prigent on Q2 2020 Results - Earnings Call Transcript

GENFIT SA (GNFT) Q2 2020 Results Conference Call September 30, 2020 04:30 PM ET Company Participants Stefanie Magner - Deputy Director, Legal Affairs Pascal Prigent - CEO Dean Hum - Chief Scientific Officer and COO Conference Call Participants Thomas Smith - SVB Leerink Derek Archila - Stifel Thomas Yip -...

SA Transcripts on Seeking Alpha | October 1, 2020

Genfit reports 1H results

Genfit (GNFT): 1H GAAP EPS of -€1.36.Revenue of €867K (+142.9% Y/Y)Shares -1.13% AH.Press Release...

Seeking Alpha | September 30, 2020

The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3) Akouos Inc (NASDAQ: AKUS ) FibroGen Inc (NASDAQ: FGEN )(reacted to an adverse clinical readout for a rival drug to treat chronic kidney disease related anemia) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) Sutro Biopharma Inc (NASDAQ: STRO ) ( reacted to announcement concerning presentation of positive data for ovarian cancer drug) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 3) Akebia Therapeutics Inc (NASDAQ: AKBA ) (announced negative safety results for a late-stage study of drug to treat chronic kidney disease-induced anemia) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Genfit SA (NASDA...

Benzinga | September 4, 2020

A Top Contender in the Race for a NASH Drug Drops Out

French biotech Genfit, which had been expected to bring one of the first drugs to market to treat nonalcoholic steatohepatitis, said it is getting out of the race altogether.

Yahoo | July 23, 2020

GENFIT: Provides Initial Update on Corporate Strategy

* Termination of the RESOLVE-IT Phase 3 clinical trial evaluating elafibranor in nonalcoholic steatohepatitis (NASH) with fibrosis   * Prioritization of elafibranor in Primary Biliary Cholangitis (PBC) and of NIS4™, GENFIT’s non-invasive technology to identify patients with at-risk NASH   * Complete corporate strategy update to be announced end of September 2020       Lille (France), Cambridge (Massachusetts, United States), July 22, 2020 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the discontinuation of the RESOLVE-IT Phase 3 clinical trial of elafibranor in adults with non-alcoholic steatohepatitis (NASH) and fibrosis.On May 11, 2020, GENFIT announced t...

Yahoo | July 22, 2020

Read More 'GNFT' Stories Here

GNFT Price Returns

1-mo 21.80%
3-mo -18.13%
6-mo -77.95%
1-year -70.53%
3-year N/A
5-year N/A
YTD -77.54%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7145 seconds.